USFDA resolution is a key for US business Dr. Reddy's Laboratories (DRL) has reported disappointing performance in Q1FY17 numbers, with its sales, operating income and PAT declining by 14%, /61% & 77% to Rs32.2bn, Rs 3.9bn & Rs 1.7bn, respectively. US sales dipped by 16% yoy to US$230mn due to pricing pressure on account of increased competition in its key molecules i.e. gValcyte & gVidaza and consequent loss of market share. DRL's RoW (Rest of the World) business dipped 53% yoy due to decline in sales in Venezuela. India business reported subdued 10% yoy growth led by new pricing policy and WPI-based annual price decline....